Bailard, Inc. Aurinia Pharmaceuticals Inc. Transaction History

Bailard, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$8.95 - $12.8 $234,489 - $335,360	-26,200 Reduced 29.11%	63,800 $641,000
Q4 2021 Feb 10, 2022	SELL	$17.78 - $33.08 $3.89 Million - $7.24 Million	-219,000 Reduced 70.87%	90,000 $2.06 Million
Q3 2021 Nov 15, 2021	SELL	$10.93 - $23.55 $666,730 - $1.44 Million	-61,000 Reduced 16.49%	309,000 $6.84 Million
Q2 2021 Aug 13, 2021	BUY	$10.0 - $14.52 $560,000 - $813,120	56,000 Added 17.83%	370,000 $4.8 Million
Q1 2021 May 13, 2021	BUY	$12.3 - $18.73 $1.27 Million - $1.93 Million	103,000 Added 48.82%	314,000 $4.08 Million
Q3 2020 Nov 10, 2020	BUY	$13.19 - $16.66 $2.12 Million - $2.68 Million	161,000 Added 322.0%	211,000 $3.11 Million
Q2 2020 Aug 12, 2020	BUY	$14.12 - $18.33 $706,000 - $916,499	50,000 New	50,000 $813,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.